By anticipating potential reactions, clinicians can prevent minor issues from disrupting a successful treatment plan
There is emerging research on the relationship between gut bacteria, GLP-1, and polycystic ovary syndrome
Pharmaceutical companies are heavily restricted in how they compensate doctors for promoting medications
Current standard-of-care therapies provide median survival of only 14-15 months, highlighting the urgent need for novel therapeutic approaches
The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study
We found a significant fold increase in the levels of several tumor suppressor and DNA repair gene protein products (GP)s at the end of 4th week during 4-week intermittent fasting (CALU, INTS6, KIT, CROCC, PIGR), and 1 week after 4-week intermittent fasting (CALU, CALR, IGFBP4, SEMA4B) compared with the levels before 4-week intermittent fasting